Taken together, these findings suggest that broad IFN-α blockade in the context of chronic, ART-suppressed HIV infection is safe and may lead to improved CD8+ T cell cytotoxic function and viral reservoir reduction during ART and better clinical outcomes upon interruption of ART. The gene discussed is IFNA1; the disease is HIV infectious disease.